Celldex Therapeutics
CLDX
54 hedge funds and large institutions have $8.8M invested in Celldex Therapeutics in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
22% more call options, than puts
Call options by funds: $163K | Put options by funds: $134K
6% more funds holding
Funds holding: 51 → 54 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.7% less ownership
Funds ownership: 27.12% → 26.42% (-0.7%)
16% less capital invested
Capital invested by funds: $10.4M → $8.8M (-$1.62M)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$503K |
| 2 |
Renaissance Technologies
New York
|
+$264K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$93.6K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$77.9K |
| 5 |
VF
Virtu Financial
New York
|
+$32.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$133K |
| 2 |
Two Sigma Investments
New York
|
-$92K |
| 3 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$85K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$76.4K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
51
IFP Advisors
Tampa,
Florida
| – | +$12 | +5 | New |
|
|
SFS
52
Sowell Financial Services
North Little Rock,
Arkansas
| – | +$30 | +13 | New |
|
53
Fidelity Investments
Boston,
Massachusetts
| – | +$46 | +20 | New |
|
54
Bank of America
Charlotte,
North Carolina
| – | +$100 | +43 | +20% |
|
CLDX Hedge Fund Activity: Q3 2019 in Review
54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2019, worth a combined $8.8M — down 16% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLDX positions and 7 closed out — a net gain of 3 holders — while 11 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $503K. The largest seller was Bridgeway Capital Management, cutting an estimated $133K.
- 54 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2019, up from 51 in Q2 2019.
- Funds reported $8.8M of Celldex Therapeutics stock for Q3 2019, down 16% quarter-over-quarter.
- 10 funds opened new Celldex Therapeutics positions in Q3 2019 and 7 closed out, a net change of +3 holders.
- The largest Celldex Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $503K added.
- The largest Celldex Therapeutics seller in Q3 2019 was Bridgeway Capital Management, an estimated $133K sold.
Based on aggregated 13F filings for Q3 2019.